Citadel Advisors LLC Has $3.70 Million Stake in Bruker Corporation (BRKR)
Citadel Advisors LLC reduced its stake in Bruker Corporation (NASDAQ:BRKR) by 34.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 128,377 shares of the medical research company’s stock after selling 67,298 shares during the quarter. Citadel Advisors LLC owned about 0.08% of Bruker Corporation worth $3,702,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Alps Advisors Inc. boosted its position in shares of Bruker Corporation by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 20,154 shares of the medical research company’s stock worth $581,000 after purchasing an additional 52 shares in the last quarter. Utah Retirement Systems boosted its position in shares of Bruker Corporation by 1.1% in the 2nd quarter. Utah Retirement Systems now owns 19,189 shares of the medical research company’s stock worth $553,000 after purchasing an additional 200 shares in the last quarter. Federated Investors Inc. PA boosted its position in shares of Bruker Corporation by 0.3% in the 2nd quarter. Federated Investors Inc. PA now owns 60,553 shares of the medical research company’s stock worth $1,746,000 after purchasing an additional 204 shares in the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of Bruker Corporation by 0.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 48,267 shares of the medical research company’s stock worth $1,126,000 after purchasing an additional 312 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Bruker Corporation by 11.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after purchasing an additional 467 shares in the last quarter. 65.42% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have recently commented on the company. BidaskClub cut Bruker Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $24.00 price target on shares of Bruker Corporation in a research report on Tuesday. Wells Fargo & Company cut Bruker Corporation from a “market perform” rating to an “underperform” rating in a research report on Wednesday, July 12th. Barclays PLC reissued an “equal weight” rating and issued a $30.00 price target (up from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Finally, Zacks Investment Research raised Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Thursday, July 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $26.70.
Bruker Corporation (BRKR) opened at 29.60 on Thursday. The company has a market capitalization of $4.70 billion, a PE ratio of 29.51 and a beta of 1.10. Bruker Corporation has a 52-week low of $19.59 and a 52-week high of $30.23. The company has a 50-day moving average price of $28.57 and a 200 day moving average price of $26.57.
Bruker Corporation (NASDAQ:BRKR) last announced its earnings results on Thursday, August 3rd. The medical research company reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The company had revenue of $414.90 million during the quarter, compared to the consensus estimate of $384.75 million. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. Bruker Corporation’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm earned $0.20 earnings per share. Equities research analysts anticipate that Bruker Corporation will post $1.12 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 22nd. Stockholders of record on Tuesday, September 5th were paid a dividend of $0.04 per share. The ex-dividend date of this dividend was Thursday, August 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.55%. Bruker Corporation’s payout ratio is currently 16.00%.
In related news, CEO Frank H. Laukien acquired 2,335 shares of the stock in a transaction dated Thursday, August 10th. The stock was acquired at an average cost of $27.39 per share, for a total transaction of $63,955.65. Following the completion of the purchase, the chief executive officer now owns 37,791,386 shares of the company’s stock, valued at approximately $1,035,106,062.54. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, VP Mark Munch sold 21,061 shares of Bruker Corporation stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the sale, the vice president now owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The disclosure for this sale can be found here. Insiders own 35.20% of the company’s stock.
WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/28/citadel-advisors-llc-has-3-70-million-stake-in-bruker-corporation-brkr.html.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR).
Receive News & Stock Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related stocks with our FREE daily email newsletter.